MTNBMatinas BioPharma Holdings, Inc.
$0.00
0.00(0.00%)
Price History
Key Statistics
052-Week Range$0.48 - $3.09
Market Cap
$5.20M
Volume
-
Avg Volume
-
P/E Ratio
-
EPS
-
Open
-
Prev Close
-
52W High
$3.09
52W Low
$0.48
Options Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Bid | Ask | Vol | Bid | Ask | Vol | |
| 0.91 | 1.04 | 125 | 0.0 | 1.87 | 0.63 | 401 |
| 1.86 | 1.41 | 275 | 0.0 | 1.83 | 2.00 | 358 |
| 1.07 | 1.90 | 443 | 0.0 | 1.60 | 0.89 | 264 |
| 0.78 | 0.94 | 748 | 0.0 | 0.01 | 1.88 | 754 |
| 1.09 | 1.30 | 165 | 0.0 | 0.33 | 0.17 | 494 |
Recent News
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
GlobeNewswire Inc.•Jun 24
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin
GlobeNewswire Inc.•Jun 13
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
GlobeNewswire Inc.•May 16
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire Inc.•May 9
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Provide a Business Update on May 9, 2024
GlobeNewswire Inc.•May 2
About MTNB
PHARMACEUTICAL PREPARATIONSXASE
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.